New application of fucoxanthin to preparation of medicine for treating alzheimer disease

A technology of Alzheimer's disease and fucoxanthin, applied in the field of fucoxanthin in the preparation of drugs for the treatment of Alzheimer's disease, can solve the problems of side effects of AChE inhibitors, achieve inhibition of Aβ fibrosis, and good safety , the effect of easy purification

Inactive Publication Date: 2016-03-23
NINGBO UNIV
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these AChE inhibitors have different degrees of side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of fucoxanthin to preparation of medicine for treating alzheimer disease
  • New application of fucoxanthin to preparation of medicine for treating alzheimer disease
  • New application of fucoxanthin to preparation of medicine for treating alzheimer disease

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment 1

[0019] Inhibition of acetylcholinesterase (AchE) by fucoxanthin

[0020] 1. Experimental materials and reagents

[0021] Fucoxanthin is extracted and purified from copper algae, and its chemical structure is as follows:

[0022] .

[0023] Experimental reagents: iodoacetylthiocholine (AChI) was purchased from sigma company, dissolved in 100mmol L -1 Na 2 HPO 4 solution, the concentration is 20mmol·L -1 . Dithiobis(2-nitrobenzoic acid) (DTNB) was purchased from LifeScience, dissolved in 100mmol L -1 Na 2 HPO 4 solution, the concentration is 5mmol L -1 . Ethylpromazine (BuChE inhibitor) was purchased from Sigma, dissolved in dimethyl sulfoxide (DMSO) at a concentration of 20 mmol L -1 .

[0024] Preparation of brain homogenate: the rats were decapitated and the brains were taken out, and the cerebral cortex was separated on ice and dried with liquid nitrogen. After weighing the cortex, add 10 times of lysis buffer (HEPES10mmol L -1 , TritonX-1000.5%, EDTA5mmol·L ...

specific Embodiment 2

[0037] Figure 5 The middle control group is untreated SH-SY5Y cells (from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences), the cells added with hydrogen peroxide are the model group, and the cells added with different concentrations of fucoxanthin 2 hours in advance are the experimental group. Cell viability was detected by MTT colorimetry. Depend on Figure 5 It can be seen that adding hydrogen peroxide to SH-SY5Y cells can lead to cell death, and adding fucoxanthin 2 hours in advance can reduce the cell death rate caused by hydrogen peroxide. It is concluded that fucoxanthin can resist the cytotoxicity caused by oxidative stress. Have neuroprotective effect. Since Aβ may generate hydrogen peroxide in cells, which may cause oxidative stress and lead to cell death, this shows that fucoxanthin may produce neuroprotection against Aβ from a perspective.

[0038] Image 6 as well as Figure 7 The middle control group is untreated cells, the cells ad...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses new application of fucoxanthin to preparation of medicine for treating the alzheimer disease. The application is characterized in that fucoxanthin is used in the aspect of preparation of the medicine for treating the alzheimer disease, particularly in the aspect of preparation of medicine inhibiting acetylcholin esterase and the aspect of preparation of medicine inhibiting Abeta fibrosis. The application has the advantage that fucoxanthin has the inhibition function on acetylcholin esterase and Abeta fibrosis.

Description

technical field [0001] The invention relates to a new application of fucoxanthin, in particular to a new application of fucoxanthin in the preparation of drugs for treating Alzheimer's disease. Background technique [0002] Fucoxanthin, also known as fucoxanthin and fucoxanthin, is widely distributed in algae such as Phaeophyceae, Diatomaceae, Chrysophyceae, and Dinophyceae, and participates in their photosynthesis. Fucoxanthin is a xanthophyll compound belonging to the carotenoid family. It has a special allene carbon skeleton and has strong antioxidant properties. It can effectively scavenge free radicals and singlet oxygen and prevent free radical damage. Modern pharmacological research has found that fucoxanthin is safe, can effectively resist oxidative stress in the human body, and has various activities such as anti-tumor, memory improvement, and weight loss. [0003] Alzheimer's disease (AD) is the most common cause of senile dementia. Due to the lack of specific cli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/336A61P25/28
CPCA61K31/336
Inventor 何山崔巍张金荣严小军王钦文段海霞林佳佳杨君泽黄凌
Owner NINGBO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap